|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | New binary polymorphisms reshape and increase resolution of the human Y chromosomal haplogroup tree显示文摘 | Karafet TM Mendez FL Meilerman MB Underhill PA Zegura SL Hammer MF | | 0，，05： | 1 |
| 2 | New binary polymorphisms reshape and increase resolution of the human ~ chromosomal haplogroup tree 显示文摘 | Karafet TM Mendez FL Meilerman MB | 2008 | Genome Research2008，18，5： | 1 |
| 3 | Identification of germ cell-specific VASA and IFITM3 proteins in hu- man ovarian endometriosis显示文摘 | Fraunhoffer NA Meilerman Abuelafia A Stella I | 2015 | J Ovarian Res2015，8，1： | 1 |
| 4 | New binary polymorphisms reshape and increase resolution of the human Y chromosomal haplogroup tree显示文摘 | Karafet TM Mendez FL Meilerman MB | 2008 | Genome Res2008，18，5： | 1 |
| 5 | New binary polymorphisms reshape and increase resolution of the human Y chromosomal haplogroup tree显示文摘 | KARAFET T M MENDEZ F L Meilerman M B | 2008 | Genome Res2008，18，5： | 1 |
| 6 | New binary polymorphisms reshape and increase resolution of the human Y chromosomal haplogroup tree 显示文摘 | Karafet TM Mendez FL Meilerman MB | 2008 | Genome Res2008，18，5： | 1 |
| 7 | Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity显示文摘Dear Editor,Pancreatic ductal adenocarcinoma(PDAC)treatment is focused on two regimens.The polychemotherapy,FOLFIRINOX(folinic acid,fluorouracil,irinotecan,oxali-platin),is used in patients with good health conditions[1],while gemcitabine,as monotherapy,in patients with poor health conditions[2–4].Gemcitabine resistance-associated pathways have been targeted to sensitize cancer cells,but the results were disappointing.Using a transcrip-tomic bioinformatics analysis combined with biological validation,we showed that glucuronidation was associ-ated with the gemcitabine resistance in PDAC,and its inhibition could switch tumors from resistant to sensitive. | Nicolas Alejandro Fraunhoffer Analía Meilerman Abuelafia Brice Chanez Martin Bigonnet Odile Gayet Julie Roques Eduardo Chuluyan Nelson Dusetti Juan Iovanna | 2022 | Cancer Communications2022，42，11： | 0 |
| 8 | Limitation and challenges in using pancreatic cancer-derived organoids as a preclinical tool显示文摘Dear Editor,Pancreatic ductal adenocarcinoma(PDAC)is a dismal disease with a fast evolution and unpredictable treatment response.Nowadays,FOLFIRINOX[1]and gemcitabine[2]are the preferred treatments with a response rate of 33%and 11%,respectively.This poor patient response has been associated with an inefficient/non-personalized treatment allocation.Consequently,developing a rapid and efficient preclinical tool to test tumor drug sensitivity for each patient is hugely needed.Biopsy patient-derived organoid(PDO)appears to be a promising tool for developing individualized treatments for patients with PDAC.Several PDO-based platforms are in development worldwide as a guide to optimize therapy by directing tailored treatments.A critical point to consider PDO as promising is that it must represent the great clinical heterogeneity of PDAC as much as possible.Moreover,PDO has displayed histological features that mimic the PDAC phenotype.These characteristics make PDO an interesting option to obtaining reliable chemo-response profiles at a reasonable timeframe for most PDAC patients. | Nicolas A.Fraunhoffer Analía Meilerman Abuelafia Nelson Dusetti Juan Iovanna | 2022 | Cancer Communications2022，42，10： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员